Impact of electronic cigarette ever use on lung function in adults aged 45-85: a cross-sectional analysis from the Canadian Longitudinal Study on Aging.
geriatric medicine
public health
respiratory medicine (see thoracic medicine)
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
27 10 2021
27 10 2021
Historique:
entrez:
28
10
2021
pubmed:
29
10
2021
medline:
4
11
2021
Statut:
epublish
Résumé
To describe the sociodemographic characteristics associated with e-cigarette ever use and to examine the impact of e-cigarette ever use on lung function impairment in an ageing population. A cross-sectional analysis of data from the Canadian Longitudinal Study on Aging. A national stratified sample of 44 817 adults living in Canadian provinces. Respondents included participants aged 45-85 and residing in the community in Canadian provinces. The Global Lung Function Initiative normative values for forced expiratory volume in the first second (FEV The prevalence of e-cigarette ever use was 6.5% and varied by sociodemographic factors including higher prevalence among individuals younger than 65 years, those with lower education attainment and those with lower annual household income. E-cigarette ever use was associated with 2.10 (95% CI 1.57 to 2.08) times higher odds of obstructive lung function impairment after adjusting for conventional cigarette smoking and other covariates. Individuals with exposure to e-cigarette ever use and 15 or more pack-years had 7.43 (95% CI 5.30 to 10.38) times higher odds for obstructive lung function impairment when compared with non-smokers and non-e-cigarette users after adjusting for covariates. Smokers with 15 or more pack-years had higher odds of restrictive lung function impairment irrespective of e-cigarette ever use. Ever use of e-cigarettes was found to be associated with obstructive lung function impairment after adjusting for covariates, suggesting that e-cigarette use may be adding to the respiratory and other chronic disease burden in the population.
Identifiants
pubmed: 34706955
pii: bmjopen-2021-051519
doi: 10.1136/bmjopen-2021-051519
pmc: PMC8552144
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e051519Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
NCHS Data Brief. 2015 Oct;(217):1-8
pubmed: 26555932
Toxicol Appl Pharmacol. 2014 Jul 1;278(1):9-15
pubmed: 24732441
Ann Intern Med. 2017 Mar 21;166(6):390-400
pubmed: 28166548
BMC Public Health. 2018 Jul 3;18(1):818
pubmed: 29970048
Prev Med. 2015 Dec;81:180-3
pubmed: 26348453
Am J Respir Crit Care Med. 2018 Feb 15;197(4):492-501
pubmed: 29053025
Eur Respir J. 2018 Apr 4;51(4):
pubmed: 29449423
Tob Control. 2010 Apr;19(2):98-103
pubmed: 20378585
Am J Med. 2019 Aug;132(8):949-954.e2
pubmed: 30853474
N Engl J Med. 2014 Jan 23;370(4):293-5
pubmed: 24350902
Chest. 2012 Jun;141(6):1400-1406
pubmed: 22194587
Lancet. 2013 Nov 16;382(9905):1629-37
pubmed: 24029165
Addict Behav. 2014 Mar;39(3):507-11
pubmed: 24290207
Lancet Respir Med. 2020 Jun;8(6):585-596
pubmed: 32526187
Int J Epidemiol. 2019 Dec 1;48(6):1752-1753j
pubmed: 31633757
Drug Alcohol Depend. 2019 Jan 1;194:363-370
pubmed: 30472577
Int J Environ Res Public Health. 2014 Apr 22;11(4):4356-73
pubmed: 24758891
PLoS One. 2015 Feb 04;10(2):e0116861
pubmed: 25651083
Inhal Toxicol. 2013 Feb;25(2):91-101
pubmed: 23363041
JAMA. 2014 Jan 8;311(2):135-6
pubmed: 24399548
Am J Physiol Regul Integr Comp Physiol. 2018 Jun 1;314(6):R834-R847
pubmed: 29384700
Int J Drug Policy. 2007 Mar;18(2):70-4
pubmed: 17689347
Cardiovasc Toxicol. 2019 Oct;19(5):441-450
pubmed: 30963443
PLoS One. 2018 Jul 25;13(7):e0198681
pubmed: 30044773
Can J Aging. 2009 Sep;28(3):221-9
pubmed: 19860977
Am J Prev Med. 2020 Feb;58(2):182-190
pubmed: 31859175
Am J Respir Crit Care Med. 2018 Jul 1;198(1):67-76
pubmed: 29481290
Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L662-L672
pubmed: 30091379
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
BMC Pulm Med. 2021 Jul 13;21(1):231
pubmed: 34256746
J Hazard Mater. 2018 Feb 15;344:549-557
pubmed: 29102637
JAMA Netw Open. 2018 Jul 6;1(3):e180789
pubmed: 30646032
Eur Respir J. 2018 Feb 7;51(2):
pubmed: 29437942
Am J Physiol Lung Cell Mol Physiol. 2017 Aug 1;313(2):L193-L206
pubmed: 28522559
BMC Public Health. 2010 May 04;10:231
pubmed: 20441579
Ther Adv Chronic Dis. 2020 Oct 10;11:2040622320961617
pubmed: 33101622
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
PLoS One. 2017 Nov 7;12(11):e0187399
pubmed: 29112988
Int J Hyg Environ Health. 2014 Jul;217(6):628-37
pubmed: 24373737
Nicotine Tob Res. 2016 May;18(5):715-9
pubmed: 26525063
Am J Mens Health. 2019 Jan-Feb;13(1):1557988318806073
pubmed: 30318975
Ann N Y Acad Sci. 2012 Jul;1259:39-46
pubmed: 22758635
Am J Physiol Lung Cell Mol Physiol. 2016 Jul 1;311(1):L135-44
pubmed: 27288488
J Gen Intern Med. 2017 Dec;32(12):1315-1322
pubmed: 28884423
Thorax. 2016 Dec;71(12):1119-1129
pubmed: 27558745